Zymeworks Inc.
ZYMEHealthcareNASDAQBiotechnology · Last scanned Jun 3, 2026
Scan Results
Daily timeframeZymeworks Inc., a biotechnology company, develops biotherapeutics for the treatment of cancer, inflammation, and autoimmune diseases. The company carries a $1.77B market cap, placing it firmly in the small-cap category. The company's platforms include Azymetric multispecific antibody platform; Drug Conjugate platform that includes a suite of proprietary cytotoxins comprising topoisomerase and microtubulin inhibiting toxins, stable linkers, and conjugation technologies; EFECT platform, which consists of a set of modifications to the Fc region of antibodies; and ProTECT, a tumor-specific immune co-stimulation platform.
Market Cap
$1.77B
Beta
1.19
P/E (TTM)
—
P/E (Fwd)
46.75
EPS (TTM)
$-1.37
EPS (Fwd)
$0.52
ROE
-42.0%
ROA
-15.8%
Cash
$364.7M
Total Debt
$17.0M
Free CF
-$45.5M
52W Change
97.6%
Annual Financials
Cash vs Debt
The balance sheet looks solid with $364.7M in cash comfortably exceeding the $17.0M debt load. A net cash position generally provides financial flexibility during uncertain economic periods. The company is burning cash, with free cash flow at -$45.5M. This typically occurs when a company is investing aggressively in growth, but sustained cash burn can strain the balance sheet. ROE of -42.0% points to negative capital efficiency, indicating how much profit the company produces per dollar of shareholder equity. Revenue has been uneven over recent years, ranging from $412.5M to $106.0M.
The strong cash position relative to debt provides a financial cushion that reduces balance sheet risk. Negative free cash flow means the company is currently spending more than it generates, which may require future fundraising or debt if the trend continues. Understanding these risk dimensions helps frame what to watch going forward as conditions evolve for Zymeworks Inc. and its sector.